All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
Japanese study of elotuzumab plus lenalidomide/dexamethasone in NDMM patients
The MM Hub is delighted to report on the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, GA. On Sunday 10 December 2017 an oral abstract session took place entitled: Session: 653. Myeloma: Therapy, excluding Transplantation: Upfront Therapy for Multiple Myeloma: Induction and Maintenance. In this session, Di. Mitsuo Hori from the Ibaraki Prefectural Central Hospital, Ibaraki, Japan, presented the findings of a phase II study. The title of the talk (Abstract 434) was: Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan. This article is based on the pre-published abstract.
The study was designed to test the effects of elotuzumab with lenalidomide plus dexamethasone in comparison with lenalidomide and dexamethasone alone, in patients with Newly Diagnosed Multiple Myeloma (NDMM). Elotuzumab has shown efficacy in Relapsed Refractory MM (RRMM), but this is the first trial testing efficacy in NDMM.
Key Findings:
- Patients (pts), n = 82 total
- Elotuzumab, lenalidomide, dexamethasone (ELd) = 40 pts
- Lenalidomide, dexamethasone (Ld) = 42 pts
- Median Age = 72 years (ELd) and 73 years (Ld)
- Clinical Response Results
- CR: 3% ELd vs 5% Ld
- VGPR: 38% ELd vs 21% Ld
- PR: 43% ELd vs 45% Ld
- Progressive Disease: 0% ELd vs 2% Ld
- ORR: 88% ELd vs 74% Ld
- Most common adverse events (AEs) (ELd vs Ld): constipation (43% vs 31%), pyrexia (35% vs 7%), rash (28% vs 36%), diarrhea (28% vs 21%), nasopharyngitis (25% vs 26%), dysgeusia (23% vs 19%), malaise (23% vs 2%), peripheral edema (20% vs 14%), neutropenia (20% vs 14%), leukopenia (20% vs 7%), and back pain (18% vs 21%)
- Most common grade 3-4 AEs (ELd vs Ld): neutropenia (10% vs 7%) and leukopenia (15% vs 0%)
While data for PFS and OS are not yet available, ELd did show improved ORR when compared to Ld therapy. ELd had a comparable safety profile, which makes this therapeutic option attractive for further study in patients with NDMM.
References
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?